BLRX - BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day

Catalyst stack for the next 6 weeks -

Oct 23-27 - ESMO in Madrid

Nov 13 - SNO dual posters in Philadelphia

2026 - PDAC interim with Regeneron still unannounced (H2 2026)

H1 2027 - Phase 1 human efficacy data

**BLRX - Two SNO Presentations Confirmed for November 13**

BioLineRx just dropped a PR this morning confirming two GLIX1 posters at the Society for Neuro-Oncology annual meeting in Philadelphia on November 13.

One poster covers preclinical GBM data including TMZ-resistant tumor models. The other covers the Phase 1/2a trial design presented by the actual Northwestern investigator running the study.

This comes 15 days before ESMO where the ovarian cancer and PARP inhibitor synergy data is expected to be presented.